New smart drug targets Hard-to-Treat cancers in early trial
NCT ID NCT07439094
First seen Feb 28, 2026 · Last updated May 24, 2026 · Updated 14 times
Summary
This study tests a new drug, CKD-703, for people with advanced solid tumors or a type of lung cancer (non-small cell lung cancer) that has not responded to standard treatments. The drug is designed to deliver a cancer-killing agent directly to cancer cells that have a specific marker (c-Met). The goal is to see if it is safe and effective. About 140 adults will take part in this early-phase trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Gabrail Cancer Center
RECRUITINGOhio City, Ohio, 44718, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.